The basis of this latter recommendation is the Swedish Inflammatory Bowel Disease Registry (SWIBREG) (Eriksson 2017), which reported clinical remission of 54% at a median follow‐up of 17 months amongst a cohort of people with active CD (86% of whom had previously failed TNF inhibitor therapy). This evidence concerns the gene TNF and inflammatory bowel disease.